SRC and neoplasm: c‐Src is significantly activated (Tyr530 dephosphorylation) in various tumors.[6] Inhibition of c‐Src phosphorylation at Tyr530 can promote tumor progression and chemoresistance.[7] Several kinase inhibitors targeting c‐Src phosphorylation sites have been used in clinical trials.[8, 9] However, tumor cells often acquire drug resistance during treatment.